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a b s t r a c t
We investigated the antidepressant-like action of 5 compounds belonging to the selenophene class. The
involvement of ERK and CREB activation in this action was also demonstrated. In the experiment 1, time-
course and dose-response effect of H-DPS, CH3-DPS, Cl-DPS, F-DPS and CF3-DPS were accompanied in
the mouse forced swimming test (FST). Firstly, animals received compounds at a dose of 50 mg/kg, by
intragastric (i.g.) route, at different times (15–240 min) before test. Results showed that the peak of
maximum anti-despair behavior induced by Cl-DPS, F-DPS and CF3-DPSwas at 30 min; maximum effect
of H-DPS and CH3-DPS was found at 60 min, which was maintained until 120 min. Regarding dose–
response effect, all compounds reduced immobility time and increased latency for the first episode of
immobility at a dose of 50 mg/kg. In addition, F-DPS also showed antidepressant-like action at a dose of
25 mg/kg, whilst H-DPS, CH3-DPS, Cl-DPS and CF3-DPS were not effective at lower doses. Thus, F-DPS
was chosen for further investigation of its mechanism of action. Experiment 2 showed that treatment of
animals with F-DPS (50 mg/kg, i.g.) significantly increased phosphorylated ERK1/2 levels in the
prefrontal cortex and hippocampus; however, pCREB levels were not affected. Additionally, in the
experiment 3 anti-immobility effect of F-DPS was completely blocked by pretreatment of animals with
PD 98,059, an inhibitor of ERK phosphorylation, suggesting that ERK signalling activation is involved in
its antidepressant-like action in mice. Together our data appoint F-DPS as a promising molecule for the
development of a new antidepressant therapy.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Organic forms of selenium have been suggested as relevant
biologic agents (Nogueira and Rocha, 2011). Over the last decade
preclinical studies have demonstrated that several organosele-
nium compounds have pharmacological properties including anti-
oxidant, anticonvulsant, neuroprotective and antidepressant
actions (Bruning et al., 2011; Dias et al., 2014; Gai et al., 2013;
Mahadevan et al., 2013; Pinton et al., 2013; Wilhelm et al., 2012).
We highlight the selenophene class, a specific group of heterocyclic
selenium-containing molecules whose members have been shown to
produce antidepressant-like properties (Gai et al., 2014, 2013, 2012;
Gay et al., 2010). A recent study showed that the administration of
a single dose of 3-chalcogen selenophenes (50 mg/kg) reduced the
immobility time in the mouse forced swimming test (FST); structure–
activity relationship studies demonstrated that the phenyl group at
the 2-position and an organoselenium group at the 3-position of the
five-member ring are essential for their antidepressant-like activity
(Gai et al., 2012). However, although the antidepressant-like action
selenophene compounds is known, the pharmacological profile of
3-chalcogen selenophenes was not further investigated. Furthermore,
mechanisms involved in their antidepressant-like action remain still
unclear.
Although most studies focus on serotonergic and noradrenergic
systems (Millan, 2004), recent evidences have identified modifica-
tions of intracellular signalling proteins and target genes that
could contribute to the pharmacological action of antidepressant
therapy (Blendy, 2006; Carreno and Frazer, 2014; Kuo et al., 2013;
Reus et al., 2011). Modulation of mitogen-activated protein kinase
(MAPK) pathways and the transcription factor CREB (cAMP-
response element-binding protein) are molecular targets for anti-
depressants (Blendy, 2006; Kuo et al., 2013). CREB is upregulated
by antidepressant treatment, and increasing CREB levels in rodent
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models results in antidepressant-like behaviors (Blendy, 2006;
Carreno and Frazer, 2014; Reus et al., 2011). Phosphorylation, and
therefore activation of CREB can be induced by a number of
upstream signalling cascades, including MAPK/ERK (Blendy,
2006). The mitogen activated protein kinase (MAPK) pathway
is a major signalling system that regulates cellular responses
and activation of the MAPK cascade plays a critical role in the
pathophysiology of depression (Roux and Blenis, 2004). It has been
shown that inhibition of MAPK signalling produces a depressive-
like phenotype and blocks behavioral actions of antidepressants.
Extracellular signal-regulated protein kinases (ERKs) are MAPKs
that are involved in cell proliferation and neuroprotection
(Mebratu and Tesfaigzi, 2009). Although the role of ERK in
depression is unclear, previous reports showing decreased phos-
phorylated levels of ERK1/2 in the post-mortem brain of depressed
suicide subjects and in rodent models of depression suggest an
important involvement of this protein in mood disorders (Dwivedi
et al., 2001; Feng et al., 2003). Furthermore, recent studies have
demonstrated a positive modulation of ERK isoforms by antide-
pressant drugs such as fluoxetine and reboxetine (First et al., 2013;
Kuo et al., 2013).
Taking into account the above mentioned points, the main
objective of this study was to demonstrate the profile of
antidepressant-like action of selenophene compounds in mice
as well as to investigate the participation of ERK and CREB
phosphorylation in this effect.
2. Materials and methods
2.1. Animals
The experiments were conducted using male Swiss mice (25–
30 g) maintained at 22–25 1C with free access to water and food,
under a 12:12 h light/dark cycle, with lights on at 7:00 a.m. All
manipulations were carried out between 08.00 a.m. and 04.00 p.m
and mice were acclimated to the behavioral room at least 2 h
before the test. The experiments were performed according to a
randomized schedule and each animal was used only once in each
test. The animals were used according to the guidelines of the
Committee on Care and Use of Experimental Animal Resources of
the Federal University of Santa Maria, Brazil (# 124/2010). The
procedures in this study were performed in accordance with the
NIH Guide for the Care and Use of Laboratory Animals. All efforts
were made to minimise animals suffering and to reduce the
number of animals used in the experiments.
2.2. Drugs
2,5-Diphenyl-3-(phenylseleno)-selenophene (H-DPS), 2,5-diphe-
nyl-3-(4-methylphenylseleno)-selenophene (CH3-DPS), 2,5-diphenyl-
3-(4-chlorophenylseleno)-selenophene (Cl-DPS), 2,5-diphenyl-3-
(4-fluorophenylseleno)-selenophene (F-DPS) and 2,5-diphenyl-3-(3-
trifluoromethylphenylseleno)-selenophene (CF3-DPS) (Fig. 1), were
prepared and characterised in our laboratory by the method pre-
viously described (Stein et al., 2008). Analysis of the 1HNMR and
13CNMR spectra showed analytical and spectroscopic data in full
agreement with its assigned structure. The chemical purity of studied
compound (99.9%) was determined by GC/MS.
Specific antibody against ERK1/2 phosphorylated (pERK1/2)
was obtained from Cell Signalling Technologys. Antibody against
CREB phosphorylated on Ser133 (pCREB) and β-actin were
obtained from Santa Cruz Biothechnologys. PD98,059 was pur-
chased from Sigmas. All other chemicals were obtained from
analytical grade and standard commercial suppliers.
2.3. Experimental design
2.3.1. Experiment 1
This experiment was performed in order to analyse the
pharmacological profile of antidepressant-like action of seleno-
phene compounds (H-DPS, CH3-DPS, Cl-DPS, F-DPS and CF3-DPS)
in the mouse forced swimming test (FST).
To assess the time-course of antidepressant-like action of
selenophene compounds, separate groups of mice received a
single administration of canola oil (10 ml/kg) or H-DPS, CH3-
DPS, Cl-DPS, F-DPS and CF3-DPS at a dose of 50 mg/kg, adminis-
tered by intragastric (i.g.) route. At different times after treatment
(15, 30, 60, 120, 180 or 240 min) animals were evaluated in the FST
(n¼6–8 animals/group). Pretreatment time in which compounds
presented maximum anti-immobility effect in the FST was chosen
for performing the subsequent step (Fig. 1).
To obtain the dose–response assessment, compounds were
administered at doses of 10, 25 and 50 mg/kg, i.g., 30 min
(Cl-DPS, F-DPS and CF3-DPS) or 60 min (H-DPS and CH3-DPS)
before FST (n¼6–8 animals/group). Animals were also evaluated
in the locomotor activity monitor (LMA) in order to rule out any
interference of locomotion in the FST (Fig. 1).
Since F-DPS produced antidepressant-like action at lower
doses than other organoselenium compounds, it was chosen for
performing experiments 2 and 3.
2.3.2. Experiment 2
To investigate whether ERK1/2 phosphorylation is modulated
by F-DPS, firstly mice received a single i.g. dose of F-DPS 50 mg/kg
or canola oil (10 ml/kg; n¼4/group). Thirty min after treatment
animals were then killed by decapitation and hippocampi and
prefrontal cortices were removed for determination of pERK1/2
(Fig. 1). Since MAP kinases, like ERK, regulate the activities of
several transcription factors, such as CREB, pCREB expression was
also determined. Because total protein levels are generally no
modulated after a short period, only phosphorylated proteins were
quantified.
Additionally, since single treatment did not modify pCREB
levels, we performed a repeated treatment with F-DPS in order
to analyse this protein. Compound was administered at a dose of
50 mg/kg, i.g, during 3 consecutive days and hippocampus and
prefrontal cortex of mice were removed 30 min after the last dose
for pCREB expression (Fig. 1).
In a separate group of animals, F-DPS (50 mg/kg, i.g.) or canola
oil (10 ml/kg; n¼4/group) were administered to mice. After
30 min, mice were anaesthetised and brains were perfused with
paraformaldehyde solution for pERK1/2 staining (Fig. 1).
2.3.3. Experiment 3
In order to assess the antidepressant-like action of F-DPS in the
tail suspension test (TST), mice were previously treated with
canola oil (10 ml/kg, n¼6–8) or F-DPS at doses of 10, 25 and
50 mg/kg (i.g.; n¼6–8) and subjected to the TST after 30 min.
To test the hypothesis that the antidepressant-like action of
F-DPS is mediated through a modulation of ERK phosphorylation,
a separated group of animals was treated with saline (5 μl/site) or
PD98,059 (a MEK inhibitor, 20 μg/site), by i.c.v. route, one hour
before the canola oil or F-DPS administration (50 mg/kg. i.g.; n¼
6/group). The TST was carried out 30 min after F-DPS treatment
(Fig. 1).
2.4. Spontaneous locomotor activity
To discard non-specific effects of treatments, spontaneous loco-
motor activity of mice was performed in the locomotor activity
monitor (LMA). LMA is a Plexiglas cage (454545 cm3) surrounded
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by a frame consisting of 32 photocells mounted on opposite walls
(16 L16W, spaced 2 cm apart) that continuously tracks the animal's
movement. After a previous habituation during 1 min, animals were
placed in the center of the apparatus and allowed to freely explore the
arena during 4 min. Motor activity was monitored with the Insights
Monitor Activity System. Data were collected in the form of photo-
beam breaks as an indication of activity within different predeter-
mined “zones” in the open field using Monitor Activitys software
(Insight). Number of crossings and rearings, average velocity (mm/s)
and total distance traveled (dm) were recorded.
2.5. FST
The FST is one of the most widely used tools for evaluation of
antidepressant drugs, antidepressant efficacy of new compounds,
and experimental manipulations that are aimed at rendering or
preventing depressive-like states. The procedure used in this study
was based on that previously described (Porsolt et al., 1979).
Mice were gently placed in an inescapable cylindrical container
(1025 cm2) that was filled with water (19 cm, 2571 1C) and
their escape related mobility behavior (latency for the first
immobility episode and total duration of floating) was measured
by a blinded observer during a 6 min period by using a stopwatch.
Latency was defined as the amount of time that elapsed between
placing the mouse in the tank and the first instance of each
behavioral occurrence. Each mouse was judged to be immobile
when it ceased struggling and remained floating motionless in the
water, making only those movements necessary to keep its head
above water.
2.6. TST
The TST was performed in a quiet experimental room according
to the method reported by Steru and collaborators (Steru
et al., 1985). Each mouse was suspended by its tail to an horizontal
wooden bar located inside a yellow plastic box (40 cm
46 cm40 cm) approximately 30 cm above the floor. The mouse
was secured to the bar by adhesive tape placed 1 cm from the tip
of the tail, such that the mouse's head was about 20 cm above the
floor. The trial was conducted for 6 min during which a blinded
observer scored the latency for the first immobility episode and
total duration of immobility by using a stopwatch. The mouse was
considered immobile only when it hung passively and completely
motionless. Mice that climbed their tails were eliminated from
further analyses.
2.7. Intracerebroventricular (i.c.v.) injection
The i.c.v. injection was carried out as previously described
(Haley and McCormick, 1957) and modified (Laursen and
Belknap, 1986), with the bregma fissure as a reference point. A
0.4 mm external diameter hypodermic needle was briefly attached
to a cannula, which was linked to a 25 μl Hamilton syringe,
inserted perpendicularly through the skull no more than 2 mm
into the brain of the mouse. A volume of 5 μl was then adminis-
tered in the left lateral ventricle. The injection was given over 30 s,
and the needle remained in place for another 30 s in order to avoid
the reflux of the substances injected. The injection site was 1 mm
to the right or left from the mid-point on a line drawn through to
the anterior base of the ears. In order to avoid interference in the
behavioral testing, no anesthetic drug was administered. Animals
were immobilised during the injection.
2.8. Western blot analysis
After F-DPS treatment, animals were killed by decapitation,
brains were removed and prefrontal cortex and hippocampus
were dissected in a near-freezing environmental to avoid the
rapid post-mortem degradation of phosphoproteins. The hippo-
campi and prefrontal cortices were homogenised in ice-cold
ysis buffer containing 25 mM TrisHCl (pH 7.5), 25 mM NaCl,
5 mM EGTA, 2.5 mM EDTA, 2 mM NaPP, 4 mM PNFF, 1 mM Na3VO4,
1 mM PMSF, 20 μg/ml leupeptin, 50 μg/ml aprotinin, 0.1 % SDS. The
homogenate was centrifuged at 9000 g for 20 min at 4 1C, the
low speed pellet was discarded. Samples were stored at 80 1C till
analysis. The supernatant (whole cell lysate) was separated on 10 %
SDS-PAGE and transferred onto nitrocellulose membranes
(120 min at 100 V) using standard procedures. Membranes were
blocked in PBST (PBS containing 0.1 % Tween) containing 5% nonfat
dry milk for 120 min. Following washes, blots were incubated
Fig. 1. Schematic representation of the experimental design of this study.
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overnight at 4 1C with specific antibodies against pERK1/2
(1:1000), pCREB (1:500) and β-actin (1:3000 dilution). After being
washed with PBS containing 0.1% Tween, the nitrocellulose mem-
brane was incubated with a horseradish peroxidase-conjugated
anti-rabbit IgG secondary antibody (1:5000) and left for 2 h at
room temperature. Blots were then extensively washed according
to the manufacturer's instruction and developed using enhanced
chemiluminescence detection system (Pierce, Milan, Italy). Exposi-
tion and developing time used was standardized for all the blots.
Optical density measurements were performed by dividing the
intensity of the bands by the intensity of the housekeeping protein
β-actin, used as loading control, at each time point. Measurements
in control samples were assigned a relative value of 100%.
2.9. Protein determination
Protein concentration was measured by biuret method using
bovine serum albumin (1 mg/ml) as the standard (Gornall et al.,
1949).
2.10. Tissue preparation and immunofluorescence
After F-DPS treatment mice were anaesthetised with 4% chloral
hydrate and perfused through the left cardiac ventricle with 10 ml
of a cold fixative (4% paraformaldehyde in 100 mM phosphate
buffer). After perfusion, animals were subjected to decapitation
and the brain tissues were quickly removed, postfixed for 18 h
with the same fixative at 4 1C, and transferred to 10%, then 20%,
and then 30% sucrose solution. Brains were cut on a cryostat and
sections (40 mM) were stored at 80 1C in an anti-freeze cryopro-
tectant solution (28% glycerol/28% ethylene glycol) till analysis.
After preincubation in 5 mg/ml BSA/0.3% Triton-X-100/PBS,
sections were incubated overnight at 4 1C with primary antibody
at optimised working dilution. pERK antibody (1:50, SantaCruz
Biothechnology Inc, CA, USA) was detected by Alexa 488-
conjugated rabbit secondary antibody (1:200; Invitrogen, Carls-
bad, CA). Sections were coverslipped using Vectorshield mounting
medium with DAPI (Vector Laboratories, Burlingame, CA). A Leica
DF 350 FX microscope with appropriate excitation and emission
filters for each fluorophore was used to acquire representative
images. Images were acquired with 20 to 40 objectives using
a digital camera.
2.11. Statistical analysis
All experimental results are given as the mean7S.E.M. First,
we evaluated the normality of data using the D'Agostino and
Pearson omnibus normality test. Comparisons between experi-
mental and control groups in Experiments 1 (FST and LMA) and 3
(TST) were performed by one-way analysis of variance (ANOVA)
followed by Newman–Keuls test for post hoc comparison when
appropriate. Results from pERK1/2 and pCREB levels (Experiment
2) were analyzed by using unpaired t-test. Blocking effect of
PD98,059 on the antidepressant-like action of F-DPS in the TST
was analyzed by two-way ANOVA followed by Newman–Keuls
test. Main effects of first order interactions are presented only
when interaction was not significant. All analyses were performed
using the STATISTICA for Windows software Version 7 (StatSoft,
Oklahoma, USA). Probability values less than 0.05 (Po0.05) were
considered as statistically significant.
3. Results
3.1. Selenophene compounds produce antidepressant-like action in
the FST without any change in locomotor activity of animals
Our results showed that all selenophene compounds tested in
this study showed antidepressant-like actions in the mouse FST.
However, the pharmacological profile (dose and pretreatment
time) was different for each drug.
As shown in Figs. 2A and B, acute treatment with H-DPS
(50 mg/kg, i.g.) significantly modified total immobility time
[F(5,34)¼15.49, Po0.001; Fig. 2A] and latency for the first episode
of immobility in the FST [F(5,34)¼2.56, Po0.05; Fig. 2B]. Post hoc
analyzes showed that H-DPS decreased the immobility duration at
60 (64.3%, Po0.001) and 120 (53.8%, Po0.001) min after a single
administration. Latency was increased at 60 min after treatment
(47.2%, Po0.01). Treatment of animals with H-DPS at doses of 10
and 25 mg/kg, 60 min before FST, did not produce any significant
difference in the immobility time and latency for the first episode
of immobility when compared to the control group (P40.05;
Table 1).
In a similar way to H-DPS, treatment of mice with CH3-DPS, at
a dose of 50 mg/kg, produced a significant effect on immobility
time [F(5,36)¼7.40, Po0.001; Fig. 2C] and latency in the FST
[F(5,36)¼3.01, Po0.05; Fig. 2D]. Total immobility time of mice
was decreased around of 30% (Po0.01) after 60 and 120 min of
CH3-DPS treatment whilst latency for the first episode was
increased around of 57.5% (Po0.05) at the pretreatment time of
60 min when compared to the vehicle-treated group. Doses of 10
and 25 mg/kg, 60 min before FST, did not produce significant effect
(P40.05; Table 1).
Treatment of animals with Cl-DPS produced the longest
antidepressant-like action when compared with other seleno-
phene compounds (Fig. 2). Latency [F(6,48)¼6.56, Po0.001;
Fig. 2E] and immobility duration [F(6,47)¼5.09, Po0.001; Fig. 2F]
were significantly modified after a single dose of 50 mg/kg Cl-DPS.
Post hoc analyzes showed that Cl-DPS decreased immobility at
pretreatment times of 30 min (22.6%, Po0.05), 60 min (31.4%,
Po0.05;), 120 min (34.5%, Po0.01) and 180 min (32.7%, Po0.01).
Latency for the first episode of immobility was increased around of
47.6% (Po0.01; 30 min), 50.5% (Po0.001; 60 min), 36.9%
(Po0.05; 120 min) and 35.9% (Po0.05; 180 min) after single
treatment with Cl-DPS. Administration of Cl-DPS at doses of 10
and 25 mg/kg, 60 min before FST, did not produce significant
antidepressant-like action (P40.05; Table 1).
Figs. 2G and H shows the pharmacological profile of F-DPS in
the FST. One-way ANOVA yielded a significant effect of F-DPS on
total immobility time [F(3,23)¼17.97, Po0.001; Fig. 2G] and latency
for the first episode of immobility [F(3,23)¼6.86, Po0.01; Fig. 2H].
At 30 min after a single dose of 50 mg/kg, animals treated with
F-DPS showed a decrease in the total immobility duration (47.5%,
Po0.001) and an increase in latency (103.2%, Po0.01). Moreover,
whilst a dose of 10 mg/kg was not effective in the FST (P40.05),
administration of F-DPS at a dose of 25 mg/kg produced a
significant antidepressant-like action in the FST: immobility time
was decreased at around 67.3% and latency was increased at
approximately 53% when compared to the control group treated
with vehicle (Table 1).
Finally, Figs. 2I and J shows the antidepressant-like action of
CF3-DPS. Similar to the other selenophene compounds, our results
demonstrated that acute treatment with CF3-DPS produced a
significant anti-immobility effect in the FST [F(4,29)¼4.50,
Po0.01; Fig. 2I]. Latency for the first episode of immobility was
also modified by treatment with this organoselenium compound
[F(4,29)¼2.28, Po0.05; Fig. 2J]. Post hoc comparison showed that
at 30 min after CF3-DPS treatment (50 mg/kg) immobility duration
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Fig. 2. Effect of acute treatment with selenophene compounds on depression-related behavior in the FST. (A), (C), (E), (G) and (I) represent the total immobility time; (B), (D),
(F), (H) and (J) represent the latency to the first episode of immobility. H-DPS (A and B), CH3-DPS (C and D), Cl-DPS (E and F), F-DPS (G and H) and CF3-DPS (I and J) were
administered to mice at a dose of 50 mg/kg, i.g. Animals performed FST at different times (15–240 min) after treatment. Values are expressed as mean 7 S.E.M. of 6–8
animals. Data were analyzed by using a one-way analysis of variance (ANOVA), followed by the Newman–Keuls test. Asterisks denote the significance level when compared
to the control group treated with vehicle: (n) Po0.05, (nn) Po0.01 and (nnn) Po0.001.
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of mice in the FST was significantly decreased (50.6%, Po0.05)
whilst latency was increased (57.1%, Po0.01). Despair parameters
in the FST were not modified by lower doses of CF3-DPS (10 and
25 mg/kg, P40.05; Table 1).
Regarding locomotor activity of mice acutely treated with
selenophene compounds, statistical analysis showed that neither
the number of crossings and rearings, velocity nor total distance
travelled were modified by H-DPS, CH3-DPS, Cl-DPS, F-DPS or
CF3-DPS at doses of 10, 25 and 50 mg/kg (P40.05; Table 2).
3.2. F-DPS increases ERK phosphorylation in hippocampus and
prefrontal cortex of mice
Fig. 3 shows the effect of acute treatment with F-DPS (50 mg/
kg, i.g., 30 min) on ERK1/2 phosphorylation in hippocampus of
mice. An unpaired t-test revealed a significant difference between
Control and F-DPS groups for pERK1 [t(6)¼3.86, Po0.01] and
pERK2 [t(6)¼7.45, Po0.001] levels in hippocampus of mice. ERK1
phosphorylation was increased around of 100% whilst pERK2
levels showed an increase of 121%.
In a similar way, pERK1/2 levels were also increased in
prefrontal cortex after treatment with F-DPS [t(6)¼5.50, Po0.01
and t(6)¼17.96, Po0.001, respectively; Fig. 4]. A single dose of
50 mg/kg F-DPS, given by i.g. route 30 min earlier, was effective in
increasing phosphorylated ERK1 (61%) and ERK2 (111%) levels in
prefrontal cortex of mice.
The increase on phosphorylation of ERK1/2 after a single dose
of F-DPS was not accompanied by CREB phosphorylation.
Phosphorylated CREB levels were not modified by single F-DPS
treatment both in hippocampus [t(6)¼0.53, P40.05; Fig. 3] and
prefrontal cortex [t(6)¼2.12, P40.05; Fig. 4]. Similarly, there was
not any modulation on pCREB expression after repeated treatment
with F-DPS. An unpaired t-test revealed no difference between
vehicle and F-DPS administration (3 doses of 50 mg/kg) on
phosphorylation of CREB in hippocampus [t(6)¼2.12, P40.05]
and prefrontal cortex [t(6)¼1.31, P40.05] (Fig. 5).
We performed immunofluorescence experiments to detect the
expression and localisation of p-ERK in the hippocampus after
acute F-DPS administration. p-ERK immunolabeling was detected
in both CA3 (Fig. 6A and C) region and dentate gyrus (Fig. 6E and
G). F-DPS selectively increased ERK phosphorylation within the
dentate gyrus (Fig. 6F and H) whereas in the CA3 region the
number of p-ERK positive cells following F-DPS treatment (Fig. 6B
and D) were comparable to that of control (Fig. 6A and C).
3.3. Inhibition of ERK phosphorylation blocks antidepressant-like
action of F-DPS in the mouse TST
Fig. 7 shows the effect of acute treatment with F-DPS on
immobility time and latency for the first episode of immobility in
the TST. One-way ANOVA yielded a significant effect of F-DPS on total
immobility time [F(3,27)¼21.47, Po0.001; Fig. 7A] and latency for the
first episode of immobility [F(3,7)¼10.73, Po0.001; Fig. 7B]. Animals
treated with F-DPS at doses of 25 and 50mg/kg, given 30min earlier
by i.g. route, showed a reduction in the total immobility duration
around of 52.4%, (Po0.001) and 62.4%, (Po0.001), respectively.
Latency in the TST was increased after acute treatment with F-DPS
at doses of 25 mg/kg (42.5%, Po0.01) and 50mg/kg (58.4%, Po0.001).
A dose of 10 mg/kg was not effective in the TST (P40.05).
Two-way ANOVA of total immobility time in the TST revealed a
significant PD98,059 F-DPS interaction [F(1,20)¼4.97, Po0.05].
Results depicted in Fig. 8 show that pretreatment of mice with an
inhibitor of MEK, PD98,059 (20 mg/site, i.c.v, 60 min before F-DPS
treatment), was effective in reversing the anti-immobility effect of
F-DPS (50 mg/kg, i.g.) in the mouse TST (Po0.01).
4. Discussion
In the present study, we provided further evidence that acute
administration of 3-chalcogen selenophenes exerts antidepressant-
like effect in mice. H-DPS, CH3-DPS, Cl-DPS, F-DPS and CF3-DPS
significantly reduced immobility in the FST without any locomotor-
enhancing effect. A close inspection of the results also revealed that
the fluorophenyl portion appears to contribute for the potency of
selenophene compounds since F-DPS was effective at lower doses
than other compounds. Furthermore, acute treatment with F-DPS
promoted a significant increase on phosphorylated ERK levels
in prefrontal cortex and hippocampus of mice. Besides, the
antidepressant-like effect of F-DPS evaluated in the TST was blocked
by PD98,059, an inhibitor of ERK phosphorylation (MEK inhibitor).
Taken together, the results of this study indicated that ERK
phosphorylation is involved in the acute antidepressant-like action
of F-DPS in mice.
Among all animal models, the FST remains one of the most
used tools for screening antidepressants (Petit-Demouliere et al.,
2005). Selenophenes tested in this study were effective in redu-
cing total immobility and increasing latency in the FST, suggesting
an antidepressant-like action (Costa et al., 2013; Petit-Demouliere
et al., 2005). Since locomotor changes may give false positive
effects in this test, animals were observed in the locomotor activity
monitor, which demonstrated that selenophenes did not change
the number of crossings, rearings, velocity and total distance
travelled. Thus it is unlikely that the effect of selenophenes
observed in the FST is based on stimulation of general motor
Table 1
Effect of acute treatment with selenophene compounds (dose-range: 10–50 mg/kg)
on depression-related behavior in the mouse forced swimming test (FST).
Latency (s) Immobility time (s)
H-DPS (mg/kg, i.g., 60 min)
0 47.873.5 170.475.6
10 51.573.6 167.5712.7
25 52.874.5 174.5724.6
50 68.372.0b 60.8712.0c
CH3-DPS (mg/kg, i.g., 60 min)
0 55.573.8 221.278.0
10 56.373.9 197.5711.8
25 69.776.3 181.2712.5
50 90.077.9b 135.7715.0c
Cl-DPS (mg/kg, i.g., 30 min)
0 58.075.5 210.076.0
10 61.375.3 164.7726.6
25 72.878.0 174.7716.7
50 88.876.8a 107.2714.0b
F-DPS (mg/kg, i.g., 30 min)
0 50.574.7 163.278.0
10 50.075.6 145.2724.4
25 77.278.1a 53.374.6c
50 80.075.0a 54.877.9c
CF3-DPS (mg/kg, i.g., 30 min)
0 51.374.4 201.3719.4
10 57.675.1 172.5711.0
25 51.872.5 191.2713.3
50 75.575.2b 101.8713.8b
Selenophene compounds were administered by intragastric (i.g.) route 30 or
60 min before evaluation in the FST. Values are expressed as mean7S.E.M of 6–8
animals/group. Data were analysed by using a one-way analysis of variance
(ANOVA), followed by Newman–Keuls test. Asterisks denote the significance levels
when compared to the vehicle group.
a Po0.05.
b Po0.01.
c Po0.001.
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Table 2
Locomotor parameters of mice acutely treated with selenophene compounds (dose-range: 10–50 mg/kg).
Number of crossings Number of rearings Velocity (mm/s) Distance (dm)
H-DPS (mg/kg, i.g., 60 min)
0 358.7742.0 10.071.8 25.173.8 62.279.0
10 364.4747.7 10.471.6 29.574.2 70.079.1
25 319.8762.4 8.071.6 23.975.0 55.1712.2
50 366.3742.7 12.672.5 30.571.0 64.275.7
CH3-DPS (mg/kg, i.g., 60 min)
0 359.7740.5 9.272.5 25.575.9 57.1713.5
10 346.7737.2 11.872.1 27.572.4 64.675.6
25 327.8762.4 11.672.8 34.172.5 70.3712.7
50 373.7755.8 10.772.7 29.272.6 60.879.5
Cl-DPS (mg/kg, i.g., 30 min)
0 404.8755.9 11.572.3 31.674.8 73.8711.9
10 406.5765.9 12.371.4 35.274.8 84.2711.6
25 401.5736.2 15.571.7 36.972.7 82.2710.9
50 406.0749.0 15.371.4 39.273.4 90.079.8
F-DPS (mg/kg, i.g., 30 min)
0 349.8735.1 10.371.1 24.973.2 53.379.0
10 367.7754.6 10.072.3 32.274.9 62.876.6
25 365.8749.5 1272.6 27.574.4 70.2710.9
50 332.7749.7 12.572.0 26.573.3 66.979.0
CF3-DPS (mg/kg, i.g., 30 min)
0 389.7740.9 11.171.6 27.274.0 60.979.1
10 402.2742.0 9.071.4 24.473.7 46.777.9
25 394.3756.6 9.971.8 24.373.2 53.477.9
50 364.8 743.1 10.271.2 28.373.5 60.879.8
Selenophene compounds were administered by intragastric (i.g.) route 30 or 60 min before evaluation in the locomotor activity monitor. Values are expressed as mean7S.E.M
of 6–8 animals/group. Data were analysed by using a one-way analysis of variance (ANOVA), followed by Newman–Keuls test.
Fig. 3. Effect of acute treatment with F-DPS on phosphorylation of ERK1/2 and
CREB in hippocampus of mice. F-DPS was administered at a dose of 50 mg/kg, i.g
and hippocampus was removed after 30 min of treatment. Values are expressed as
mean 7 S.E.M. of 4 animals. Data were analyzed by using unpaired t-test. Asterisk
denotes the significance level when compared to the control group: (n) Po0.05.
Representative qualitative Western blotting analysis at the top of the figure, graphic
shows representative quantification of the proteins immunocontent normalised to
β-actin protein.
Fig. 4. Effect of acute treatment with F-DPS on phosphorylation of ERK1/2 and
CREB in prefrontal cortex of mice. F-DPS was administered at a dose of 50 mg/kg,
i.g and prefrontal cortex was removed after 30 min of treatment. Values are
expressed as mean 7 S.E.M. of 4 animals. Data were analyzed by using unpaired
t-test. Asterisk denotes the significance level when compared to the control group:
(n) Po0.05. Representative qualitative Western blotting analysis at the top of the
figure, graphic shows representative quantification of the proteins immunocontent
normalised to β-actin protein.
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activity, providing evidence that 3-chalcogen selenophenes have
antidepressant-like action in mice.
Accordingly, as previously demonstrated by our research group,
the administration of selenophenes Cl-DPS, F-DPS and CF3-DPS
(50 mg/kg, i.g. route) reduced significantly the total immobility
time of mice when they were administered at 30 min before FST
Fig. 5. Effect of repeated treatment with F-DPS on CREB phosphorylation in
hippocampus and prefrontal cortex of mice. F-DPS was administered at the dose
of 50 mg/kg, i.g, during 3 days. Hippocampus and prefrontal cortex were removed
30 min after the last dose of F-DPS. Values are expressed as mean 7 S.E.M. of
4 animals. Data were analyzed by using unpaired t-test. Representative qualitative
Western blotting analysis at the top of the figure, graphic shows representative
quantification of the proteins immunocontent normalised to β-actin protein.
CTRL F-DPS CTRL F-DPS
CA3 DG 
Fig. 6. Phospho-ERK (pERK) labeling in the dorsal hippocampal formation of F-DPS-treated mice. F-DPS was administered at the dose of 50 mg/kg, thirty minutes before
brain perfusion. In CA3, F-DPS-induced pERK immunostaining (B, low magnification; D, high magnification) is comparable to that of control mice (A, low magnification;
C, high magnification). In the dentate gyrus (DG), the number of labeled neurons is substantially increased in the F-DPS-treated mice (F, low magnification;
H, high magnification) in comparison with control mice (E, low magnification; G, high magnification). Scale bars 100 mm.
Fig. 7. Effect of acute treatment with F-DPS on depression-related behavior in the
TST. (A) represents latency to the first episode of immobility and (B) shows the total
immobility time. F-DPS (10–50 mg/kg, i.g.) was administered 30 min before testing.
Values are expressed as mean 7 S.E.M. of 6 animals. Data were analyzed by using a
one-way analysis of variance (ANOVA), followed by the Newman–Keuls test.
Asterisks denote the significance level when compared to the control group: (nn)
Po0.01 and (nnn) Po0.001.
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(Gai et al., 2012). Besides confirming these data, in the present
study, our results showed that the anti-immobility effect of Cl-DPS
was maintained up to 180 min after administration, whilst the
antidepressant-like action induced by both F-DPS and CF3-DPS
was significant at only 30 min. Regarding effects of H-DPS and
CH3-DPS, in the present study we showed for the first time the
ability of these selenophenes in reducing the despair behavior in
the mouse FST. Recently, we have already demonstrated that
administration of H-DPS and CH3-DPS at a dose of 50 mg/kg,
30 min before test, was not effective in reducing immobility time
(Gai et al., 2012), which was confirmed in the present study.
However, when the test was carried out at 60 and 120 min after
treatment, both compounds showed a significant antidepressant-
like action. These data further appoint to a significant structure–
activity relationship and suggest that chemical modifications
performed on selenophene structures could alter their pharmaco-
logical profile, mainly due pharmacokinetic changes. In order to
confirm this hypothesis, our research group is already performing
a research project to investigate the absorption, distribution,
metabolism and/or excretion profile of selenophene compounds.
Despite the fast and short-acting of F-DPS, this compound
produced antidepressant-like action at lower doses than H-DPS,
CH3-DPS, Cl-DPS and CF3-DPS. In fact, fluorine has played a
particularly important and historical role in the development of
biologically active agents and the presence of 4-fluorophenyl group
appears to be essential for optimum potency of some neuroleptic
agents (Granger and Albu, 2005; Kirk, 2006). Fluorophenyl group is
also found in the structure of other antidepressant drugs such as
serotonine reuptake inhibitors, like paroxetine, citalopram and
escitalopram. Interestingly, recent studies have demonstrated the
involvement of serotonergic system in the antidepressant-like
action of F-DPS (Gai et al., 2013; Gay et al., 2010). Acute anti-
immobility effect of this selenophene compound was significantly
blocked by serotoninergic receptor antagonists and both acute and
subchronic treatments with F-DPS inhibited serotonin uptake in a
synaptosomal preparation from prefrontal cortex and hippocampus
of mice (Gai et al., 2013; Gay et al., 2010). Thus, we considered F-
DPS as the most promising selenophene to further investigate the
mechanisms involved on its antidepressant-like action.
In addition to effects on monoamines, novel theories propose
that signal pathway related to synaptic plasticity may be the
mechanism of antidepressant action. It is now well established
that antidepressants affect different signalling pathways like that
producing phosphorylation of CREB (Alboni et al., 2010; Blendy,
2006; Carreno and Frazer, 2014; First et al., 2013; Kuo et al., 2013;
Reus et al., 2011). Previous researches indicated that the ERK-CREB
signal system may be involved in the molecular mechanism of
depression (Qi et al., 2006) and some antidepressant therapies
increase both phosphorylated ERK and CREB levels in brain of
rodents after repeated treatment (Carreno and Frazer, 2014;
Musazzi et al., 2010; Qi et al., 2008; Tardito et al., 2009). Wherever,
while early peak of ERK activation is commonly observed, CREB
phosphorylation is generally seen only after days or weeks after
antidepressant treatment (Di Benedetto et al., 2012). Although
F-DPS did not modulate pCREB levels, even after repeated admin-
istration, pERK levels were significantly increased after acute
treatment. ERK is the most-studied member of the MAPK family,
and the ERK pathway is the major convergence point in all signal
pathways, regulating cellular growth and differentiation and
neuronal plasticity. ERK1 and ERK2 are prominently found in
hippocampus and prefrontal cortex which are brain regions most
likely to be implicated in stress response and depression (Ortiz et
al., 1995). It was previously reported that repeated treatment with
fluoxetine, a classical antidepressant drug, increases phosphoryla-
tion of ERK1/2 but not non-phosphorylated proteins in prefrontal
cortex and hippocampus of rats (Qi et al., 2008; Tardito et al.,
2009). Interestingly, we observed a significant increase (around
2 times) of both pERK1 and pERK2 isoforms in prefrontal cortex
and hippocampus of mice after acute treatment with F-DPS.
Immunofluorescence experiments further confirmed the ERK1/2
phosphorylation within hippocampus following F-DPS treatment
and supported the hypothesis of an involvement of hippocampal
ERK-mediated pathways in the pharmacological mechanisms of
this selenophene. Hippocampal plasticity is integrally involved in
the pathophysiology of depression and clinical evidence includes
reports of reduced hippocampal volume in magnetic resonance
imaging studies and post-mortem studies of depressive patients.
Meta-analysis of 32 publications found that volume is significantly
reduced with greater than one lifetime major depressive episode
or greater than 2 years of illness, suggesting that the observed
atrophy is resultant from the burden of illness rather than being a
pre-existing risk factor (McKinnon et al., 2009). Specifically, we
detected a selective F-DPS-induced ERK overphosphorylation in
the dentate gyrus. This appeared of particular importance since
the dentate gyrus is the area where the adult hippocampal
neurogenesis, a process downregulated by stress conditions and
depressive-like behaviours and upregulated by antidepressants,
such as SSRI (David et al., 2009; Santarelli et al., 2003), occurred.
Since our results clearly demonstrated that F-DPS modulates
ERK activation, the next step in this research was to investigate
whether this effect could be responsible for its antidepressant-like
action. In fact, pretreatment of mice with PD98,059, an inhibitor of
ERK phosphorylation, was effective in blocking the acute anti-
immobility effect of F-DPS in the TST. Based on these data our
results suggest that the ERK pathway may be the potential target
of this organoselenium compound and participate in the molecu-
lar mechanism of its antidepressant-like action.
ERK activity is able to induce phosphorylation of CREB at a
specific serine residue, serine 133, producing an active transcrip-
tion complex enabling target gene activation. The ability to detect
phosphorylation of CREB has been an important means to monitor
signalling pathways that trigger CREB activation; however, data
suggest that CREB-mediated gene expression might occur in the
absence of serine 133 phosphorylation (Conkright et al., 2003).
Thus, although phosphorylation is an indicator of CREB activation,
the ultimate measure of CREB function is gene transcription. As we
did not perform mRNA studies, one cannot exclude the modula-
tion in the function of CREB after treatment with F-DPS. Never-
theless, it is possible that short-term antidepressant-like action of
this organoselenium compound is independent of CREB modula-
tion. Recent studies have demonstrated that some antidepressant
drugs increase expression and release of neurotrophic factors via
Fig. 8. Effect of ERK phosphorylation inhibition on F-DPS-induced reduction in
total immobility time in the TST. F-DPS was administered by intragastric (i.g.) route
60 min after PD98,059 (20 mg/site) and 30 min before the test. PD98,059
was injected by intracerebroventricular (i.c.v.) way. Values are expressed as mean
7 S.E.M. of 6 animals. Asterisk denotes the significance levels when compared to
the control group treated with oil: (*) Po0.05. Hashtags denote the significance
levels when compared to the F-DPS-treated group: (##) Po0.01 (two-way ANOVA
followed by the Newman–Keuls test).
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ERK activity (First et al., 2013; Hisaoka et al., 2007). Besides,
serotonin has been showed to increase ERK activation and neuro-
trophines release via 5-HT2A receptors (Hisaoka et al., 2007).
Trophic factors such as brain-derived neurotrophic factor (BDNF)
and glial cell line-derived neurotrophic factor (GDNF) regulate
neurogenesis and neuronal plasticity, which are also improved
after antidepressant treatment (Mahar et al., 2014; Ruan
et al., 2013). Thus, these data allow us to hypothesise that
antidepressant-like action of F-DPS might be due to phosphoryla-
tion of ERK via activation of serotonergic receptors leading to
neurotrophic factors expression/release. In order to confirm it, the
effect of selenophene compounds on the hippocampal expression
of BDNF and GDNF is target of our research group in future investi-
gations.
5. Conclusion
Our results confirm that the acute antidepressant-like action of
3-chalcogen selenophenes is linked to their chemical structure. F-
DPS was the most promising selenophene tested and its
antidepressant-like action seems to involve ERK signalling activa-
tion, particularly in the prefrontal cortex and dentate gyrus of the
hippocampus. Our research group is engaged on investigating the
pharmacokinetics properties as well as understanding the mole-
cular effects of selenophene compounds that could be further
involved on their antidepressant-like action.
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